248 related articles for article (PubMed ID: 23456365)
1. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
Minden K; Klotsche J; Niewerth M; Horneff G; Zink A
Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
Niewerth M; Minden K; Klotsche J; Horneff G
Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586
[TBL] [Abstract][Full Text] [Related]
3. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
Minden K; Niewerth M; Zink A; Seipelt E; Foeldvari I; Girschick H; Ganser G; Horneff G
Rheumatology (Oxford); 2012 Aug; 51(8):1407-15. PubMed ID: 22447885
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
7. Outcome of adult patients with JIA treated with the biosimilar Benepali
Vollbach K; Tenbrock K; Wagner N; Horneff G; Klein A; Foeldvari I; Haas JP; Aries P; Gauler G; Striesow F; Hoff P; Scholz C; Tatsis S; Seipelt E; Klotsche J; Minden K
Arthritis Res Ther; 2022 Dec; 24(1):271. PubMed ID: 36514116
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
Windschall D; Müller T; Becker I; Horneff G
Clin Rheumatol; 2015 Jan; 34(1):61-9. PubMed ID: 25034081
[TBL] [Abstract][Full Text] [Related]
10. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
11. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.
Thiele F; Klein A; Windschall D; Hospach A; Foeldvari I; Minden K; Weller-Heinemann F; Horneff G
Rheumatol Int; 2021 Apr; 41(4):751-762. PubMed ID: 33590331
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
13. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
[TBL] [Abstract][Full Text] [Related]
14. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].
Horneff G
Z Rheumatol; 2010 Aug; 69(6):516-26. PubMed ID: 20532787
[TBL] [Abstract][Full Text] [Related]
15. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
Shenoi S; Wallace CA
Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Singer NG; Chon Y; Lin SL; Baumgartner SW;
Arthritis Rheum; 2009 Sep; 60(9):2794-804. PubMed ID: 19714630
[TBL] [Abstract][Full Text] [Related]
20. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.
Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM
Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]